SOVREMENNAYA PEDIATRIYA.2016.4(76):57-61; doi10.15574/SP.2016.76.57

Effectiveness of montelukast for treatment childrem with allergic rhinitis

Umanets T. R., Lapshin V. F., Matveeva S. U., Pustovalova О. I.

SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev, Ukraine

The aim was to study was evaluate the efficacy and safety of montelukast («Montel») in children with seasonal allergic rhinitis (SAR).

Material and Methods: The study was involved 30 children aged 6–12 years with seasonal allergic rhinitis. All of the children were prescribed Montel 5 mg in the form of a chewable tablet one per day in the evening during the pollen season. The criteria for assessment of the effectiveness of the treatment was: regression of the main clinical symptoms of SAD (rhinorrhea, nasal congestion, nasal itching, sneezing, ocular symptoms) according to the international scale point TSS (Total Symptoms Score), visual analogue scale (VAS); changing of the cellular composition of smears from the nasal mucosa.

Results: The study has shown that this drug had the positive therapeutic effect on nasal and ocular symptoms, as well as regression of inflammatory changes in the nasal mucosa of children with SAR.

Conclusion: The therapeutic effect of Montel was associated with anti-allergic and anti-inflammatory effects. The absence of side effects, good tolerability and high adherence allowed recommending Montel as monotherapy SAR in school-age children.

Keywords: seasonal allergic rhinitis, treatment, montelukast.

REFERENCES

1. Zharnasiek VF. 2014. Allergic rhinitis in children: current understanding of the problem, the ability to control the resistant type of rhinitis. International Review of: clinical practice and health. 1(7): 20—22.

2. Brozek JL, Bousquet J, Baena-Cagnani CE et al. 2010. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 126: 466—76.

3. Effectiveness of montelukast in pediatric patients with allergic rhinitis / O. Yilmaz, D. Altintas, C. Rondon [et al.] // International Journal of Pediatric Otorhinolaryngology. — 2013. Vol. 77. — P. 1922—1924.

4. Gentile D, Bartholow А, Valovirta Е et al. 2013. Current and Future Directions in Pediatric Allergic Rhinitis. J Allergy Clin Immunol: In Practice. 1; 3: 214—226.

5. Hansen TE, Evjenth B, Holt J. 2013. Increasing prevalence of asthma, allergic rhinoconjunctivitis and eczema among schoolchildren: three surveys during the period 1985—2008. Foundation Acta Paediatrica. 102: 47—52.

6. Lagos JA, Marshall GD. 2007. Montelukast in the management of allergic rhinitis. Therapeutics and Clinical Risk Management. 3(2): 327—332. http://dx.doi.org/10.2147/tcrm.2007.3.2.327

7. Turner PJ, Kemp AS. 2012. Allergic rhinitis in children. Journal of Pediatrics and Child Health. 48: 302—310.

8. Valovirta E. 2012. Managing Co-Morbid Asthma With Allergic Rhinitis: Targeting the One-Airway With Leukotriene Receptor Antagonists. WAO Journal. 5: 210—211.